Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis.
Truong, J; Lee, E K; Trudeau, M E; Chan, K K W.
; 27(4): 608-18, 2016 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-26712901
Eliciting adverse effects data from participants in clinical trials.
Emerging and Underrecognized Complications of Illicit Drug Use.
Tag SNPs for HLA-B alleles that are associated with drug response and disease risk in the Chinese Han population.
Safety Monitoring in Group A Meningococcal Conjugate Vaccine Trials: Description, Challenges, and Lessons.
Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study).
Optimizing Symptoms and Management of Febrile Neutropenia among Cancer Patients: Current Status and Future Directions.
Personalized pharmacogenomics: predicting efficacy and adverse drug reactions.
Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA.
Dose-dense FEC followed by dose-dense ixabepilone as neoadjuvant treatment for breast cancer patients: a feasibility study.
Categorization and association analysis of risk factors for adverse drug events.